Mirdametinib: First Approval.

Area of Science:

• Pharmacology
• Oncology
• Genetics

Background:

• Neurofibromatosis type 1 (NF1) is a genetic disorder characterized by tumor formation.
• Plexiform neurofibromas (PN) are a common and often disfiguring manifestation of NF1.
• Current treatment options for symptomatic NF1-PN are limited, particularly for those not amenable to surgical resection.

Purpose of the Study:

• To summarize the development milestones of mirdametinib.
• To highlight the regulatory approval of mirdametinib for NF1-associated PN.
• To provide an overview of mirdametinib's therapeutic potential in NF1.

Main Methods:

• Review of clinical development data for mirdametinib.
• Analysis of regulatory submission and approval processes in the USA and EU.
• Summary of ongoing clinical trials for other indications.

Main Results:

• Mirdametinib (GOMEKLI™) received US FDA approval as the first therapy for NF1-associated PN in adults and children aged 2 years and older.
• The therapy is indicated for symptomatic PN not amenable to complete resection.
• Marketing authorization application is under review in the EU, and trials for pediatric low-grade glioma are ongoing.

Conclusions:

• Mirdametinib represents a significant advancement in the treatment of NF1-associated PN.
• The approval offers a new therapeutic option for patients with limited treatment alternatives.
• Further research is exploring mirdametinib's efficacy in other NF1-related conditions.